Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population

British Journal of Clinical Pharmacology

Volumn 41, Issue 5, 1996, Pages 425-427

  Mcmurrough, J ^a   Mcleod, H L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

assay; dehydrogenase; dihydropyrimidine; methodology; pharmacogenetics

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE;

ADULT; ARTICLE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MONONUCLEAR CELL; NORMAL HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; UNITED KINGDOM; VOLUNTEER;

EID: 0029918519     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.34212.x     Document Type: Article

References (10)

1. Gonzalez FJ, Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci 1995; 16: 325-327.
2. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986; 6: 781-784.
3. Fleming RA, Milano GA, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899-2902.
4. Lu Z-H, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implications in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-5438.
5. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 1991; 68: 499-501.
6. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-2253.
7. Spector T, Cao S, Rustum YM, Harrington JA, Porter DJT. Attenuation of the antitumor activity of 5-Fluorouracil by (R)-5,6-dihydrouracil. Cancer Res 1995; 55: 1239-1241.
8. Meinsma R, Fernandez-Salguero P, Van Kuilenburg ABP, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uraciluria. DNA and Cell Biology 1995; 14: 1-6.
9. Milano G, Fischel JL, Etienne MC, et al. Inhibition of dihydropyrimidine dehydrogenase by α-interferon: experimental data on human tumor cell lines. Cancer Chemother Pharmacol 1994; 34: 147-152.
10. McLeod HL, Douglas F, Oates M, et al. Topoisomerase I and II activity in human breast, cervix, lung, and colon cancer. Int J Cancer 1994; 59: 607-611.